B-cell tolerance in transplantation: Is repertoire remodeling the answer?

Expert Review of Clinical Immunology

Volumn 5, Issue 6, 2009, Pages 703-723

  Parsons, Ronald F ^a   Vivek, Kumar ^a   Redfield, Robert R ^a   Migone, Thi Sau ^b   Cancro, Michael P ^c   Naji, Ali ^c   Noorchashm, Hooman ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Allograft; B cell; BLyS; Homeostasis; Rejection; Selection; Tolerance

Indexed keywords

ALEMTUZUMAB; APRIL PROTEIN; ATACICEPT; AUTOANTIGEN; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR ANTIBODY; B CELL MATURATION ANTIGEN; BELIMUMAB; CD19 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; COMPLEMENT COMPONENT C3D RECEPTOR; EPRATUZUMAB; IMMUNOGLOBULIN D; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD40; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRE B CELL RECEPTOR; PROTEIN BCL XL; PROTEIN BNIP3; PROTEIN P100; RITUXIMAB; STEROID; TACROLIMUS; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOGRAFT; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; KIDNEY ALLOGRAFT REJECTION; LUPUS VULGARIS; NONHUMAN; ONTOGENY; ORGAN TRANSPLANTATION; PROTEIN FUNCTION; REVIEW;

EID: 77949798194     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.63     Document Type: Review

References (199)

1. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N. Engl. J. Med. 355(19), 1967-1977 (2006).
2. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63(7), 977-983 (1997).
3. Luan FL, Steffick DE, Ojo AO. Steroidfree maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy? Kidney Int. (2009) (Epub ahead of print).
4. Deeks ED, Keating GM. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection. Drugs 69(11), 1483-1512 (2009).
5. Scherer MN, Banas B, Mantouvalou K et al. Current concepts and perspectives of immunosuppression in organ transplantation. Langenbecks Arch. Surg. 392(5), 511-523 (2007).
6. Scandling JD, Busque S, Dejbakhsh-Jones S et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N. Engl. J. Med. 358(4), 362-368 (2008).
7. Fudaba Y, Spitzer TR, Shaffer J et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am. J. Transplant. 6(9), 2121-2133 (2006).
8. Fehr T, Sykes M. Clinical experience with mixed chimerism to induce transplantation tolerance. Transpl. Int. 21(12), 1118-1135 (2008).
9. Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation 86(3), 377-383 (2008).
10. Porcheray F, Wong W, Saidman SL et al. B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans. Am. J. Transplant. 9(9), 2126-2135 (2009).
11. Pescovitz MD. B cells: a rational target in alloantibody-mediated solid organ transplantation rejection. Clin. Transplant. 20(1), 48-54 (2006).
12. Zarkhin V, Li L, Sarwal M. To B or not to B? B-cells and graft rejection. Transplantation 85(12), 1705-1714 (2008).
13. Wood KJ. Is B cell tolerance essential for transplantation tolerance? Transplantation 79(Suppl. 3), S40-S42 (2005).
14. Vongwiwatana A, Tasanarong A, Hidalgo LG, Halloran PF. The role of B cells and alloantibody in the host response to human organ allografts. Immunol. Rev. 196, 197-218 (2003).
15. Meffre E, Wardemann H. B-cell tolerance checkpoints in health and autoimmunity. Curr. Opin. Immunol. 20(6), 632-638 (2008).
16. Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat. Rev. Immunol. 5(10), 807-817 (2005).
17. Monroe JG. Molecular mechanisms regulating B cell responsiveness and tolerance. Transplantation 79(Suppl. 3), S12-S13 (2005).
18. Becker YT, Samaniego-Picota M, Sollinger HW. The emerging role of rituximab in organ transplantation. Transpl. Int. 19(8), 621-628 (2006).
19. Sarwal M, Chua MS, Kambham N et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N. Engl. J. Med. 349(2), 125-138 (2003).
20. Colvin RB. Pathology of chronic humoral rejection. Contrib. Nephrol. 162, 75-86 (2009).
21. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am. J. Transplant. 4(3), 438-443 (2004).
22. Lachmann N, Terasaki PI, Budde K et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 87(10), 1505-1513 (2009).
23. Wang R, Wang H, Chen J et al. C4d deposition in allograft renal biopsies is an independent risk factor for graft failure. Nephrology (Carlton) 14(5), 527-532 (2009).
24. Kedainis RL, Koch MJ, Brennan DC, Liapis H. Focal C4d+ in renal allografts is associated with the presence of donorspecific antibodies and decreased allograft survival. Am. J. Transplant. 9(4), 812-819 (2009).
25. Shapiro-Shelef M, Calame K. Regulation of plasma-cell development. Nat. Rev. Immunol. 5(3), 230-242 (2005).
26. Schwartzberg PL, Mueller KL, Qi H, Cannons JL. SLAM receptors and SAP influence lymphocyte interactions, development and function. Nat. Rev. Immunol. 9(1), 39-46 (2009).
27. Rasheed AU, Rahn HP, Sallusto F, Lipp M, Muller G. Follicular B helper T cell activity is confined to CXCR5hiICOShi CD4 T cells and is independent of CD57 expression. Eur. J. Immunol. 36(7), 1892-1903 (2006).
28. McCausland MM, Yusuf I, Tran H, Ono N, Yanagi Y, Crotty S. SAP regulation of follicular helper CD4 T cell development and humoral immunity is independent of SLAM and Fyn kinase. J. Immunol. 178(2), 817-828 (2007).
29. Kim CH, Lim HW, Kim JR, Rott L, Hillsamer P, Butcher EC. Unique gene expression program of human germinal center T helper cells. Blood 104(7), 1952-1960 (2004).
30. Lee PC, Zhu L, Terasaki PI, Everly MJ. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 88(4), 568-574 (2009).
31. Mizutani K, Terasaki P, Rosen A et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am. J. Transplant. 5(9), 2265-2272 (2005).
32. Sureshkumar KK, Hussain SM, Zimmer BW, Marcus RJ. Emerging role of alemtuzumab in renal and renal-pancreas transplantation. Expert Opin. Biol. Ther. 8(10), 1605-1625 (2008).
33. Kaufman DB, Leventhal JR, Gallon LG, Parker MA. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas- kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results. Am. J. Transplant. 6(2), 331-339 (2006).
34. Cai J, Terasaki PI, Bloom DD et al. Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. Transplantation 78(6), 919-924 (2004).
35. Knechtle SJ, Pirsch JD, H Fechner J Jr et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am. J. Transplant. 3(6), 722-730 (2003).
36. Fan X, Ang A, Pollock-Barziv SM et al. Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat. Med. 10(11), 1227-1233 (2004).
37. West LJ. B-cell tolerance following ABO-incompatible infant heart transplantation. Transplantation 81(3), 301-307 (2006).
38. Aoyagi T, Yamashita K, Suzuki T et al. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy. Am. J. Transplant. 9(8), 1732-1741 (2009).
39. Clatworthy MR, Watson CJ, Plotnek G et al. B-cell-depleting induction therapy and acute cellular rejection. N. Engl. J. Med. 360(25), 2683-2685 (2009).
40. Tarlinton DM, Batista F, Smith KG. The B-cell response to protein antigens in immunity and transplantation. Transplantation 85(12), 1698-1704 (2008).
41. Liu C, Noorchashm H, Sutter JA et al. B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat. Med. 13(11), 1295-1298 (2007).
42. Miller JP, Stadanlick JE, Cancro MP. Space, selection, and surveillance: setting boundaries with BLyS. J. Immunol. 176(11), 6405-6410 (2006).
43. Crowley JE, Scholz JL, Quinn WJ 3rd et al. Homeostatic control of B lymphocyte subsets. Immunol. Res. 42(1-3), 75-83 (2008).
44. Osmond DG, Rolink A, Melchers F. Murine B lymphopoiesis: towards a unified model. Immunol. Today 19(2), 65-68 (1998).
45. Osmond DG, Rico-Vargas S, Valenzona H et al. Apoptosis and macrophage-mediated cell deletion in the regulation of B lymphopoiesis in mouse bone marrow. Immunol. Rev. 142, 209-230 (1994).
46. Osmond DG, Melchers F, Paige CJ. Pre-B cells in mouse bone marrow: in vitro maturation of peanut agglutinin binding B lymphocyte precursors separated from bone marrow by fluorescence-activated cell sorting. J. Immunol. 133(1), 86-90 (1984).
47. Osmond DG. Population dynamics of bone marrow B lymphocytes. Immunol. Rev. 93, 103-124 (1986).
48. Melchers F, Rolink A, Grawunder U et al. Positive and negative selection events during B lymphopoiesis. Curr. Opin. Immunol. 7(2), 214-227 (1995).
49. Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J. Exp. Med. 173(5), 1213-1225 (1991).
50. Hardy RR, Li YS, Allman D, Asano M, Gui M, Hayakawa K. B-cell commitment, development and selection. Immunol. Rev. 175, 23-32 (2000).
51. Li Y, Ma L, Shen J, Chong AS. Peripheral deletion of mature alloreactive B cells induced by costimulation blockade. Proc. Natl Acad. Sci. USA 104(29), 12093-12098 (2007).
52. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435(7042), 590-597 (2005).
53. Goodnow CC. Nossal and Pike 1975: a turning point in the effort to define self-tolerance mechanisms. J. Immunol. 179(9), 5617-5618 (2007).
54. Nossal GJ, Pike BL. Evidence for the clonal abortion theory of B-lymphocyte tolerance. J. Exp. Med. 141(4), 904-917 (1975).
55. Norvell A, Mandik L, Monroe JG. Engagement of the antigen-receptor on immature murine B lymphocytes results in death by apoptosis. J. Immunol. 154(9), 4404-4413 (1995).
56. Nemazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 337(6207), 562-566 (1989).
57. Hartley SB, Crosbie J, Brink R, Kantor AB, Basten A, Goodnow CC. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membranebound antigens. Nature 353(6346), 765-769 (1991).
58. Nemazee D, Buerki K. Clonal deletion of autoreactive B lymphocytes in bone marrow chimeras. Proc. Natl Acad. Sci. USA 86(20), 8039-8043 (1989).
59. Russell DM, Dembic Z, Morahan G, Miller JF, Burki K, Nemazee D. Peripheral deletion of self-reactive B cells. Nature 354(6351), 308-311 (1991).
60. Cyster JG, Hartley SB, Goodnow CC. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature 371(6496), 389-395 (1994).
61. Shokat KM, Goodnow CC. Antigeninduced B-cell death and elimination during germinal-centre immune responses. Nature 375(6529), 334-338 (1995).
62. Cyster JG, Goodnow CC. Antigen-induced exclusion from follicles and anergy are separate and complementary processes that influence peripheral B cell fate. Immunity 3(6), 691-701 (1995).
63. Treml JF, Hao Y, Stadanlick JE, Cancro MP. The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem. Biophys 53(1), 1-16 (2009).
64. Miosge LA, Goodnow CC. Genes, pathways and checkpoints in lymphocyte development and homeostasis. Immunol. Cell Biol. 83(4), 318-335 (2005).
65. Rolink AG, Schaniel C, Andersson J, Melchers F. Selection events operating at various stages in B cell development. Curr. Opin. Immunol. 13(2), 202-207 (2001).
66. Louzoun Y, Friedman T, Luning Prak E, Litwin S, Weigert M. Analysis of B cell receptor production and rearrangement. Part I. Light chain rearrangement. Semin. Immunol. 14(3), 169-190; discussion 221-1122 (2002).
67. Liu Y, Li L, Kumar KR et al. Lupus susceptibility genes may breach tolerance to DNA by impairing receptor editing of nuclear antigen-reactive B cells. J. Immunol. 179(2), 1340-1352 (2007).
68. Verkoczy LK, Martensson AS, Nemazee D. The scope of receptor editing and its association with autoimmunity. Curr. Opin. Immunol. 16(6), 808-814 (2004).
69. Gay D, Saunders T, Camper S, Weigert M. Receptor editing: an approach by autoreactive B cells to escape tolerance. J. Exp. Med. 177(4), 999-1008 (1993).
70. Kouskoff V, Lacaud G, Pape K, Retter M, Nemazee D. B cell receptor expression level determines the fate of developing B lymphocytes: receptor editing versus selection. Proc. Natl Acad. Sci. USA 97(13), 7435-7439 (2000).
71. Stadanlick JE, Kaileh M, Karnell FG et al. Tonic B cell antigen receptor signals supply an NF-kB substrate for prosurvival BLyS signaling. Nat. Immunol. 9(12), 1379-1387 (2008).
72. Goodnow CC, Crosbie J, Adelstein S et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 334(6184), 676-682 (1988).
73. Erikson J, Radic MZ, Camper SA, Hardy RR, Carmack C, Weigert M. Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. Nature 349(6307), 331-334 (1991).
74. Treml LS, Quinn WJ 3rd, Treml JF, Scholz JL, Cancro MP. Manipulating B cell homeostasis: a key component in the advancement of targeted strategies. Arch. Immunol. Ther. Exp. (Warsz) 56(3), 153-164 (2008).
75. Yan M, Brady JR, Chan B et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr. Biol. 11(19), 1547-1552 (2001).
76. Smith SH, Cancro MP. Cutting edge: B cell receptor signals regulate BLyS receptor levels in mature B cells and their immediate progenitors. J. Immunol. 170(12), 5820-5823 (2003).
77. Mackay F, Woodcock SA, Lawton P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190(11), 1697-1710 (1999).
78. Batten M, Groom J, Cachero TG et al. BAFF mediates survival of peripheral immature B lymphocytes. J. Exp. Med. 192(10), 1453-1466 (2000).
79. Moore PA, Belvedere O, Orr A et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285(5425), 260-263 (1999).
80. Schneider P, MacKay F, Steiner V et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. 189(11), 1747-1756 (1999).
81. Warnatz K, Salzer U, Rizzi M et al. B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc. Natl Acad. Sci. USA 106(33), 13945-13950 (2009).
82. Kalled SL. The role of BAFF in immune function and implications for autoimmunity. Immunol. Rev. 204, 43-54 (2005).
83. Hsu BL, Harless SM, Lindsley RC, Hilbert DM, Cancro MP. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J. Immunol. 168(12), 5993-5996 (2002).
84. Enzler T, Bonizzi G, Silverman GJ et al. Alternative and classical NF-k B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 25(3), 403-415 (2006).
85. Hatada EN, Do RK, Orlofsky A et al. NF-k B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-k B2 p100 to p52 in quiescent mature B cells. J. Immunol. 171(2), 761-768 (2003).
86. Woodland RT, Fox CJ, Schmidt MR et al. Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood 111(2), 750-760 (2008).
87. Day ES, Cachero TG, Qian F et al. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry 44(6), 1919-1931 (2005).
88. Cao M, Chen L, Shan XX, Zhang SQ. Immunological effects of refolded human soluble BAFF synthesized in Escherichia coli on murine B lymphocytes in vitro and in vivo. Jpn J. Physiol. 55(4), 221-227 (2005).
89. Hymowitz SG, Patel DR, Wallweber HJ et al. Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J. Biol. Chem. 280(8), 7218-7227 (2005).
90. Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat. Rev. Drug Discov. 5(3), 235-246 (2006).
91. Harless SM, Lentz VM, Sah AP et al. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curr. Biol. 11(24), 1986-1989 (2001).
92. Shulga-Morskaya S, Dobles M, Walsh ME et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J. Immunol. 173(4), 2331-2341 (2004).
93. Grech AP, Amesbury M, Chan T, Gardam S, Basten A, Brink R. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kB activation in mature B cells. Immunity 21(5), 629-642 (2004).
94. Chung JB, Silverman M, Monroe JG. Transitional B cells: step by step towards immune competence. Trends Immunol. 24(6), 343-349 (2003).
95. Yu M, Parsons RF, Rostami S et al. In vivo BLyS/BAFF neutralization induces donor specific transplantation tolerance to murine islet allografts. Am. J. Transplant. 9(Suppl. 2), 728 (2009).
96. Morecki S, Leshem B, Eid A, Slavin S. Alloantigen persistence in induction and maintenance of transplantation tolerance. J. Exp. Med. 165(6), 1468-1480 (1987).
97. Hamano K, Rawsthorne MA, Bushell AR, Morris PJ, Wood KJ. Evidence that the continued presence of the organ graft and not peripheral donor microchimerism is essential for maintenance of tolerance to alloantigen in vivo in anti-CD4 treated recipients. Transplantation 62(6), 856-860 (1996).
98. Lang J, Nemazee D. B cell clonal elimination induced by membrane-bound self-antigen may require repeated antigen encounter or cell competition. Eur. J. Immunol. 30(2), 689-696 (2000).
99. Sykes M, Shimizu I, Kawahara T. Mixed hematopoietic chimerism for the simultaneous induction of T and B cell tolerance. Transplantation 79(Suppl. 3), S28-S29 (2005).
100. Yang YG, deGoma E, Ohdan H et al. Tolerization of anti-Gala1-3Gal natural antibody-forming B cells by induction of mixed chimerism. J. Exp. Med. 187(8), 1335-1342 (1998).
101. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am. J. Transplant. 7(2), 408-415 (2007).
102. Yanaba K, Bouaziz JD, Matsushita T, Tsubata T, Tedder TF. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J. Immunol. 182(12), 7459-7472 (2009).
103. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118(10), 3420-3430 (2008).
104. Moore KW, OGarra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu. Rev. Immunol. 11, 165-190 (1993).
105. Gross JA, Dillon SR, Mudri S et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS. Immunity 15(2), 289-302 (2001).
106. Thien M, Phan TG, Gardam S et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20(6), 785-798 (2004).
107. Brink R. Regulation of B cell self-tolerance by BAFF. Semin. Immunol. 18(5), 276-283 (2006).
108. Quinn WJ 3rd, Noorchashm N, Crowley JE et al. Cutting edge: impaired transitional B cell production and selection in the nonobese diabetic mouse. J. Immunol. 176(12), 7159-7164 (2006).
109. Zekavat G, Rostami SY, Badkerhanian A et al. In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice. J. Immunol. 181(11), 8133-8144 (2008).
110. Kahn P, Ramanujam M, Bethunaickan R et al. Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum. 58(9), 2824-2834 (2008).
111. Marino E, Villanueva J, Walters S, Liuwantara D, Mackay F, Grey ST. CD4+CD25+ T-cells control autoimmunity in the absence of B-cells. Diabetes 58(7), 1568-1577 (2009).
112. Ding C. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Expert Opin. Biol. Ther. 8(11), 1805-1814 (2008).
113. Furie R, Stohl W, Ginzler EM et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a Phase I trial in patients with systemic lupus erythematosus. Arthritis Res. Ther. 10(5), R109 (2008).
114. Dorner T. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J. Rheumatol. Suppl. 77, 3-11 (2006).
115. Ding C, Jones G. Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline. Curr. Opin. Investig. Drugs 7(5), 464-472 (2006).
116. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann. Rheum. Dis. 66(5), 700-703 (2007).
117. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 54(3), 723-732 (2006).
118. Pers JO, Devauchelle V, Daridon C et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögrens syndrome. Arthritis Rheum. 56(5), 1464-1477 (2007).
119. Sundberg A, Samaniego M, Pirsch J et al. A pilot study of campath-1H and rituximab induction therapy combined with Cellcept to allow for a calcineurin inhibitor-free regimen after renal transplantation. Am. J. Transplant. 9(Suppl. 2), 258 (2009).
120. Bloom DD, Pauly K, Chang Z et al. BAFF dysregulation in renal transplant patients treated with campath-1H. Am. J. Transplant. 9(Suppl. 2), 226 (2009).
121. Bloom D, Chang Z, Pauly K et al. BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am. J. Transplant. 9(8), 1835-1845 (2009).
122. Xu H, He X, Liu Q et al. The abnormal high expression of B cell activating factor belonging to TNF superfamily (BAFF) and its potential role in kidney transplant recipients. Cell Mol. Immunol. 5(6), 465-470 (2008).
123. Xu H, He X, Liu Q et al. Abnormal high expression of B-cell activating factor belonging to the TNF superfamily (BAFF) associated with long-term outcome in kidney transplant recipients. Transplant Proc. 41(5), 1552-1556 (2009).
124. Zarkhin V, Sarwal MM. Microarrays: monitoring for transplant tolerance and mechanistic insights. Clin. Lab. Med. 28(3), 385-410, vi (2008).
125. Cambridge G, Leandro MJ, Teodorescu M et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 54(11), 3612-3622 (2006).
126. Everly MJ, Everly JJ, Susskind B et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 86(12), 1754-1761 (2008).
127. Watson CJ, Bradley JA, Friend PJ et al. Alemtuzumab (campath 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am. J. Transplant. 5(6), 1347-1353 (2005).
128. Basu A, Ramkumar M, Tan HP et al. Reversal of acute cellular rejection after renal transplantation with campath-1H. Transplant Proc. 37(2), 923-926 (2005).
129. Clatworthy MR, Friend PJ, Calne RY et al. Alemtuzumab (campath-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up. Transplantation 87(7), 1092-1095 (2009).
130. Di Noia JM, Neuberger MS. Molecular mechanisms of antibody somatic hypermutation. Annu. Rev. Biochem. 76, 1-22 (2007).
131. Rajewsky K. Clonal selection and learning in the antibody system. Nature 381(6585), 751-758 (1996).
132. Tarlinton D, Radbruch A, Hiepe F, Dorner T. Plasma cell differentiation and survival. Curr. Opin. Immunol. 20(2), 162-169 (2008).
133. Pereira JP, Kelly LM, Xu Y, Cyster JG. EBI2 mediates B cell segregation between the outer and centre follicle. Nature 460(7259), 1122-1126 (2009).
134. Yamauchi T, Ueki K, Tobe K et al. Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone. Nature 390(6655), 91-96 (1997).
135. Zubler RH. Naive and memory B cells in T-cell-dependent and T-independent responses. Springer Semin. Immunopathol. 23(4), 405-419 (2001).
136. Bar-Or A, Oliveira EM, Anderson DE et al. Immunological memory: contribution of memory B cells expressing costimulatory molecules in the resting state. J. Immunol. 167(10), 5669-5677 (2001).
137. Anderson SM, Tomayko MM, Ahuja A, Haberman AM, Shlomchik MJ. New markers for murine memory B cells that define mutated and unmutated subsets. J. Exp. Med. 204(9), 2103-2114 (2007).
138. Lopes-Carvalho T, Kearney JF. Marginal zone B cell physiology and disease. Curr. Dir. Autoimmun. 8, 91-123 (2005).
139. Stephens R, Ndungu FM, Langhorne J. Germinal centre and marginal zone B cells expand quickly in a second Plasmodium chabaudi malaria infection producing mature plasma cells. Parasite Immunol. 31(1), 20-31 (2009).
140. Miller DJ, Hayes CE. Phenotypic and genetic characterization of a unique B lymphocyte deficiency in strain A/WySnJ mice. Eur. J. Immunol. 21(5), 1123-1130 (1991).
141. Miller DJ, Hanson KD, Carman JA, Hayes CE. A single autosomal gene defect severely limits IgG but not IgM responses in B lymphocyte-deficient A/WySnJ mice. Eur. J. Immunol. 22(2), 373-379 (1992).
142. Rahman ZS, Manser T. B cells expressing Bcl-2 and a signaling-impaired BAFFspecific receptor fail to mature and are deficient in the formation of lymphoid follicles and germinal centers. J. Immunol. 173(10), 6179-6188 (2004).
143. Benson MJ, Dillon SR, Castigli E et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J. Immunol. 180(6), 3655-3659 (2008).
144. OConnor BP, Raman VS, Erickson LD et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199(1), 91-98 (2004).
145. Moreaux J, Cremer FW, Reme T et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 106(3), 1021-1030 (2005).
146. Scholz JL, Crowley JE, Tomayko MM et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc. Natl Acad. Sci. USA 105(40), 15517-15522 (2008).
147. Ahuja A, Anderson SM, Khalil A, Shlomchik MJ. Maintenance of the plasma cell pool is independent of memory B cells. Proc. Natl Acad. Sci. USA 105(12), 4802-4807 (2008).
148. Mitchison NA. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J. Exp. Med. 102(2), 157-177 (1955).
149. Di Rosa F, Matzinger P. Long-lasting CD8 T cell memory in the absence of CD4 T cells or B cells. J. Exp. Med. 183(5), 2153-2163 (1996).
150. Brandle D, Joergensen J, Zenke G, Burki K, Hof RP. Contribution of donor-specific antibodies to acute allograft rejection: evidence from B cell-deficient mice. Transplantation 65(11), 1489-1493 (1998).
151. Moulin V, Andris F, Thielemans K, Maliszewski C, Urbain J, Moser M. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J. Exp. Med. 192(4), 475-482 (2000).
152. Wasowska BA, Qian Z, Cangello DL et al. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice. Transplantation 71(6), 727-736 (2001).
153. Noorchashm H, Reed AJ, Rostami SY et al. B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. J. Immunol. 177(11), 7715-7722 (2006).
154. Ng YH, Li Q, Marlowe A, Hoffman R, Chalasani G. Antigen presentation by B cells promotes heart allograft rejection and development of alloreactive memory T cells. Am. J. Transplant. 8(Suppl. 2), 177-336 (2008).
155. Burns AM, Ma L, Li Y et al. Memory alloreactive B cells and alloantibodies prevent anti-CD154-mediated allograft acceptance. J. Immunol. 182(3), 1314-1324 (2009).
156. Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. 115(10), 2914-2923 (2005).
157. Yada A, Ebihara S, Matsumura K et al. Accelerated antigen presentation and elicitation of humoral response in vivo by FcgRIIB- and FcgRI/III-mediated immune complex uptake. Cell Immunol. 225(1), 21-32 (2003).
158. Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med. 359(3), 242-251 (2008).
159. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298(5601), 2199-2202 (2002).
160. Chevrier S, Genton C, Kallies A et al. CD93 is required for maintenance of antibody secretion and persistence of plasma cells in the bone marrow niche. Proc. Natl Acad. Sci. USA 106(10), 3895-3900 (2009).
161. Hu CY, Rodriguez-Pinto D, Du W et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 117(12), 3857-3867 (2007).
162. Gong Q, Ou Q, Ye S et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174(2), 817-826 (2005).
163. Cornec D, Avouac J, Youinou P, Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun. Rev. 8(6), 515-519 (2009).
164. Tsai EW, Rianthavorn P, Gjertson DW, Wallace WD, Reed EF, Ettenger RB. CD20+ lymphocytes in renal allografts are associated with poor graft survival in pediatric patients. Transplantation 82(12), 1769-1773 (2006).
165. Hippen BE, DeMattos A, Cook WJ, Kew CE 2nd, Gaston RS. Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Am. J. Transplant. 5(9), 2248-2252 (2005).
166. Martins HL, Silva C, Martini D, Noronha IL. Detection of B lymphocytes (CD20+) in renal allograft biopsy specimens. Transplant Proc. 39(2), 432-434 (2007).
167. Zarkhin V, Li L, Kambham N, Sigdel T, Salvatierra O, Sarwal MM. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am. J. Transplant. 8(12), 2607-2617 (2008).
168. Zarkhin V, Kambham N, Li L et al. Characterization of intra-graft B cells during renal allograft rejection. Kidney Int. 74(5), 664-673 (2008).
169. Pescovitz MD. The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation. Pediatr. Transplant. 8(1), 9-21 (2004).
170. Vallerskog T, Gunnarsson I, Widhe M et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin. Immunol. 122(1), 62-74 (2007).
171. Faguer S, Kamar N, Guilbeaud-Frugier C et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 83(9), 1277-1280 (2007).
172. Trivedi HL, Terasaki PI, Feroz A et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 87(10), 1555-1561 (2009).
173. Doxiadis, II, Duquesnoy RJ, Claas FH. Extending options for highly sensitized patients to receive a suitable kidney graft. Curr. Opin. Immunol. 17(5), 536-540 (2005).
174. Beimler JH, Susal C, Zeier M. Desensitization strategies enabling successful renal transplantation in highly sensitized patients. Clin. Transplant. 20(Suppl. 17), 7-12 (2006).
175. Doxiadis II, Claas FH. Transplantation of highly sensitized patients via the acceptable mismatch program or desensitization? We need both. Curr. Opin. Organ Transplant 14(4), 410-413 (2009).
176. Haririan A, Nogueira J, Kukuruga D et al. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am. J. Transplant. 9(3), 536-542 (2009).
177. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb. Haemost. 87(1), 52-57 (2002).
178. Kempton CL, White GC 2nd. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 113(1), 11-17 (2009).
179. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N. Engl. J. Med. 318(15), 947-950 (1988).
180. Gloor JM, DeGoey SR, Pineda AA et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am. J. Transplant. 3(8), 1017-1023 (2003).
181. Beimler JH, Morath C, Schmidt J et al. Successful deceased-donor kidney transplantation in crossmatch-positive patients with peritransplant plasma exchange and rituximab. Transplantation 87(5), 668-671 (2009).
182. Tanriover B, Wright SE, Foster SV et al. High-dose intravenous immunoglobulin and rituximab treatment for antibodymediated rejection after kidney transplantation: a cost analysis. Transplant Proc. 40(10), 3393-3396 (2008).
183. Ravichandran P, Natrajan T, Jaganathan R. Combination treatment of low dose anti-thymocyte globulin (ATG), rituximab and high dose sirolimus as induction agents in immune-conditioned recipients. Int. Immunopharmacol. 6(13-14), 1973-1976 (2006).
184. Tanabe K, Ishida H, Shimizu T, Omoto K, Shirakawa H, Tokumoto T. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens. Contrib. Nephrol. 162, 61-74 (2009).
185. Genberg H, Kumlien G, Wennberg L, Berg U, Tyden G. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 85(12), 1745-1754 (2008).
186. Yoon HE, Hyoung BJ, Hwang HS et al. Successful renal transplantation with desensitization in highly sensitized patients: a single center experience. J. Korean Med. Sci. 24(Suppl.), S148-S155 (2009).
187. Munoz AS, Rioveros AA, Cabanayan-Casasola CB, Danguilan RA, Ona ET. Rituximab in highly sensitized kidney transplant recipients. Transplant Proc. 40(7), 2218-2221 (2008).
188. Amante AJ, Ejercito R. Management of highly sensitized patients: Capitol Medical Center experience. Transplant Proc. 40(7), 2274-2280 (2008).
189. Ignjatovic L, Kovacevic Z, Jovanovic D et al. Our first experiences in applying an original method for removal of ABOisoagglutinins in ABO-incompatible kidney recipients. Vojnosanit Pregl. 66(2), 117-122 (2009).
190. Reinsmoen NL, Lai CH, Vo A et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 86(6), 820-825 (2008).
191. Vieira CA, Agarwal A, Book BK et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 77(4), 542-548 (2004).
192. Perry DK, Burns JM, Pollinger HS et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am. J. Transplant. 9(1), 201-209 (2009).
193. Tak PP, Thurlings RM, Rossier C et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, Phase Ib, double-blind, placebo-controlled, dose- escalating, single- and repeated-dose study. Arthritis Rheum. 58(1), 61-72 (2008).
194. Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404(6781), 995-999 (2000).
195. Gatto B. Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells. Curr. Opin. Investig. Drugs 9(11), 1216-1227 (2008).
196. Ponce R. Preclinical support for combination therapy in the treatment of autoimmunity with atacicept. Toxicol. Pathol. 37(1), 89-99 (2009).
197. Bracewell C, Isaacs JD, Emery P, Ng WF. Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther. 9(7), 909-919 (2009).
198. DallEra M, Chakravarty E, Wallace D et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, Phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 56(12), 4142-4150 (2007).
199. Boskovic S, Smith NR, Kawai T et al. Inhibitory effects of atacicept (TACI-Ig) on circulating antibodies, B cells and plasma cells in allosensitized cynomolgous monkeys. Am. J. Transplant. 8(Suppl. 2), 177-336 (2008).